Cyclohexanamine;formic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Cyclohexanamine;formic acid
• 英文别名: cyclohexanamine;formic acid
• 化学式: C7H15NO2
• 分子量: 145.2
• InChiKey: VHMQVZZBBWVYLF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.07
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  67.8
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• HEAT-EXPANDABLE MICROSPHERE, METHOD FOR PRODUCING SAME AND USE OF SAME
  申请人：Matsumoto Yushi-Seiyaku Co., Ltd.

  公开号：EP2441814A1

  公开（公告）日：2012-04-18

  A heat-expandable microspheres having high heat resistance and high solvent resistance, a production process thereof and application thereof are provided. The heat-expandable microspheres include a shell of a thermoplastic resin and a thermally vaporizable blowing agent being encapsulated therein. The thermoplastic resin includes a copolymer produced by polymerizing a polymerizable component containing a carboxyl-group-containing monomer. The surface of the heat-expandable microspheres is treated with an organic compound containing a metal of the Groups from 3 to 12 in the Periodic Table.

  本发明提供了一种具有高耐热性和高耐溶剂性的可热膨胀微球及其生产工艺和应用。 热膨胀微球包括热塑性树脂外壳和封装在其中的可热蒸发发泡剂。热塑性树脂包括通过聚合含有羧基单体的可聚合成分而产生的共聚物。热膨胀微球的表面用含有元素周期表 3 至 12 族金属的有机化合物处理。
• OPTICAL FILM, POLARIZING PLATE, AND LIQUID-CRYSTAL DISPLAY DEVICE
  申请人：Oikawa Tokuju

  公开号：US20090086130A1

  公开（公告）日：2009-04-02

  An optical film comprising a transparent film, and, on the film, at least one layer formed by applying a composition comprising a titanium compound and/or a zirconium compound and a vinyl alcohol-based resin to a surface is disclosed.
• CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
  申请人：Wityak John

  公开号：US20110183957A1

  公开（公告）日：2011-07-28

  Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.
• US3959298A
  申请人：——

  公开号：US3959298A

  公开（公告）日：1976-05-25
• US3953459A
  申请人：——

  公开号：US3953459A

  公开（公告）日：1976-04-27